Lack of ST2 aggravates glioma invasiveness, vascular abnormality, and immune suppression
(2025) In Neuro-Oncology Advances 7(1).- Abstract
Background. Glioblastoma (GBM) is the most common primary malignant brain tumor in adults, characterized by aggressive growth and a dismal prognosis. Interleukin-33 (IL-33) and its receptor ST2 have emerged as regulators of glioma growth, but their exact function in tumorigenesis has not been deciphered. Indeed, previous studies on IL-33 in cancer have yielded somewhat opposing results as to whether it is pro- or anti-tumorigenic. Methods. IL-33 expression was assessed in a GBM tissue microarray and public databases. As in vivo models we used orthotopic xenografts of patient-derived GBM cells, and syngenic models with grafted mouse glioma cells. Results. We analyzed the role of IL-33 and its receptor ST2 in nonmalignant cells of the... (More)
Background. Glioblastoma (GBM) is the most common primary malignant brain tumor in adults, characterized by aggressive growth and a dismal prognosis. Interleukin-33 (IL-33) and its receptor ST2 have emerged as regulators of glioma growth, but their exact function in tumorigenesis has not been deciphered. Indeed, previous studies on IL-33 in cancer have yielded somewhat opposing results as to whether it is pro- or anti-tumorigenic. Methods. IL-33 expression was assessed in a GBM tissue microarray and public databases. As in vivo models we used orthotopic xenografts of patient-derived GBM cells, and syngenic models with grafted mouse glioma cells. Results. We analyzed the role of IL-33 and its receptor ST2 in nonmalignant cells of the glioma microenvironment and found that IL-33 levels are increased in cells surrounding the tumor. Protein complexes of IL-33 and ST2 are mainly found outside of the tumor core. The IL-33-producing cells consist primarily of oligodendrocytes. To determine the function of IL-33 in the tumor microenvironment, we used mice lacking the ST2 receptor. When glioma cells were grafted to ST2-deficient mouse brains, the resulting tumors exhibited a more invasive growth pattern, and are associated with poorer survival, compared to wild-type mice. Tumors in ST2-deficient hosts are more invasive, with increased expression of extracellular matrix remodeling enzymes and enhanced tumor angiogenesis. Furthermore, the absence of ST2 leads to a more immunosuppressive environment. Conclusions. Our findings reveal that glia-derived IL-33 and its receptor ST2 participate in modulating tumor invasiveness, tumor vasculature, and immunosuppression in glioma.
(Less)
- author
- organization
- publishing date
- 2025
- type
- Contribution to journal
- publication status
- published
- subject
- in
- Neuro-Oncology Advances
- volume
- 7
- issue
- 1
- article number
- vdaf010
- publisher
- Oxford University Press
- external identifiers
-
- pmid:39931535
- scopus:85217904746
- DOI
- 10.1093/noajnl/vdaf010
- language
- English
- LU publication?
- yes
- id
- c0335c07-a368-43d6-a7ad-994ae244eb78
- date added to LUP
- 2025-07-03 11:14:23
- date last changed
- 2025-07-04 03:00:03
@article{c0335c07-a368-43d6-a7ad-994ae244eb78, abstract = {{<p>Background. Glioblastoma (GBM) is the most common primary malignant brain tumor in adults, characterized by aggressive growth and a dismal prognosis. Interleukin-33 (IL-33) and its receptor ST2 have emerged as regulators of glioma growth, but their exact function in tumorigenesis has not been deciphered. Indeed, previous studies on IL-33 in cancer have yielded somewhat opposing results as to whether it is pro- or anti-tumorigenic. Methods. IL-33 expression was assessed in a GBM tissue microarray and public databases. As in vivo models we used orthotopic xenografts of patient-derived GBM cells, and syngenic models with grafted mouse glioma cells. Results. We analyzed the role of IL-33 and its receptor ST2 in nonmalignant cells of the glioma microenvironment and found that IL-33 levels are increased in cells surrounding the tumor. Protein complexes of IL-33 and ST2 are mainly found outside of the tumor core. The IL-33-producing cells consist primarily of oligodendrocytes. To determine the function of IL-33 in the tumor microenvironment, we used mice lacking the ST2 receptor. When glioma cells were grafted to ST2-deficient mouse brains, the resulting tumors exhibited a more invasive growth pattern, and are associated with poorer survival, compared to wild-type mice. Tumors in ST2-deficient hosts are more invasive, with increased expression of extracellular matrix remodeling enzymes and enhanced tumor angiogenesis. Furthermore, the absence of ST2 leads to a more immunosuppressive environment. Conclusions. Our findings reveal that glia-derived IL-33 and its receptor ST2 participate in modulating tumor invasiveness, tumor vasculature, and immunosuppression in glioma.</p>}}, author = {{Wicher, Grzegorz and Roy, Ananya and Vaccaro, Alessandra and Vemuri, Kalyani and Ramachandran, Mohanraj and Olofsson, Tommie and Imbria, Rebeca Noemi and Belting, Mattias and Nilsson, Gunnar and Dimberg, Anna and Forsberg-Nilsson, Karin}}, language = {{eng}}, number = {{1}}, publisher = {{Oxford University Press}}, series = {{Neuro-Oncology Advances}}, title = {{Lack of ST2 aggravates glioma invasiveness, vascular abnormality, and immune suppression}}, url = {{http://dx.doi.org/10.1093/noajnl/vdaf010}}, doi = {{10.1093/noajnl/vdaf010}}, volume = {{7}}, year = {{2025}}, }